ArticleClinicoEconomics and outcomes research : CEOR2013

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.

Carlo Lazzaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.